ClinicalTrials.gg

Program

zimberelimab

Also written as “Zimberelimab”, “GLS-010” and “AB122”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Uterine Cervical Neoplasms · Adenocarcinoma Of Esophagus · Neoplasm Metastasis · Biliary Tract Neoplasms, led by 5 companies.

Furthest: phase 3, since Aug 19, 202220 company-led studies, 10 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Guangzhou Gloria Biosciences74 open or runningphase 3since Aug 19, 2022Aug 28, 2018Dec 2026phase 2 · NCT05909436
Arcus Biosciences60 open or runningphase 3since Oct 3, 2022Jul 17, 2018none ahead
Gilead Sciences43 open or runningphase 3since Aug 12, 2022Apr 26, 2018Jun 2028phase 3 · NCT05502237
Otsuka22 open or runningphase 3since Jul 3, 2026Jul 27, 2021Jun 2027phase 1 · NCT04999761
RemeGen11 open or runningphase 2since Nov 23, 2023Nov 23, 2023Jun 30, 2027phase 2 · NCT06155396

Also a collaborator on its studies: Merck KGaA, Darmstadt, Germany and strata-oncology.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Apr 26, 2018.

  1. Aug 29, 2019Phase 1 study in Advanced Solid TumorsArcus Biosciences · NCT04087018 · 18 enrolled · United States
  2. Jan 23, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungArcus Biosciences · NCT04262856 · 151 enrolled · United States, Australia, Canada and more
  3. Jan 29, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungArcus Biosciences · NCT04736173 · 169 enrolled · United States, Hong Kong, Malaysia and more
  4. Feb 5, 2021Phase 1 study in Advanced Solid TumorsGilead Sciences · NCT04747470 · 13 enrolled · United States
  5. Jul 27, 2021Otsuka's first study: phase 1 study in Neoplasm MetastasisNew to OtsukaOtsuka · NCT04999761 · 917 planned · Japan
  6. Aug 12, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungGilead Sciences · NCT05502237 · 1,021 enrolled · United States, Argentina, Austria and more
  7. Aug 19, 2022Phase 3 study in RecurrenceGuangzhou Gloria Biosciences · NCT05518318 · 60 planned
  8. Oct 3, 2022Phase 3 study in Adenocarcinoma Of EsophagusArcus Biosciences · NCT05568095 · 1,040 enrolled · United States, Argentina, Australia and more
  9. Nov 21, 2022Phase 2 study in Lung NeoplasmsGilead Sciences · NCT05633667 · 192 enrolled · United States, Brazil, Hong Kong and more
  10. Dec 26, 2022Phase 3 study in RecurrenceGuangzhou Gloria Biosciences · NCT05798819 · 424 planned · China
  11. May 4, 2023Phase 2 study in Solid TumorGuangzhou Gloria Biosciences · NCT05909436 · 107 planned · China
  12. Jul 26, 2023Phase 2 study in Advanced Non-Small Cell Lung CancerGuangzhou Gloria Biosciences · NCT05978401 · 152 planned · China
  13. Nov 23, 2023RemeGen's first study: phase 2 study in Uterine Cervical NeoplasmsNew to RemeGenRemeGen · NCT06155396 · 116 planned · China
  14. Jul 3, 2026Phase 3 study in Biliary Tract NeoplasmsPhase 3 reachedOtsuka · NCT07710885 · 784 planned · Australia, Japan, South Korea and more

Ahead

  1. Dec 2026Primary completion: phase 2 study in Solid TumorGuangzhou Gloria Biosciences · NCT05909436
  2. Jun 2027Primary completion: phase 1 study in Neoplasm MetastasisOtsuka · NCT04999761
  3. Jun 30, 2027Primary completion: phase 2 study in Uterine Cervical NeoplasmsRemeGen · NCT06155396
  4. Jun 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungGilead Sciences · NCT05502237

TargetBeta

PDCD1 →read by rule
“A human immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07710885Biliary Tract Neoplasms · Australia, Japan, South Korea and more3RecruitingOtsukaApr 30, 2030784
NCT06155396Uterine Cervical Neoplasms · China2RecruitingRemeGenJun 30, 2027116
NCT05978401Advanced Non-Small Cell Lung Cancer · China2Not yet recruitingGuangzhou Gloria BiosciencesApr 1, 2025152
NCT05909436Solid Tumor · China2RecruitingGuangzhou Gloria BiosciencesDec 2026107
NCT05798819Recurrence · China3RecruitingGuangzhou Gloria BiosciencesDec 31, 2029424
NCT05633667Lung Neoplasms · United States, Brazil, Hong Kong and more2Active, not recruitingGilead SciencesSep 2029192
NCT05568095Adenocarcinoma Of Esophagus · United States, Argentina, Australia and more3CompletedArcus BiosciencesAug 28, 20261,040
NCT05518318Recurrence3Not yet recruitingGuangzhou Gloria BiosciencesJun 202560
NCT05502237Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more3Active, not recruitingGilead SciencesJun 20281,021
NCT04999761Neoplasm Metastasis · Japan1RecruitingOtsukaJun 2027917
NCT04747470Advanced Solid Tumors · United States1TerminatedGilead SciencesNov 7, 202213
NCT04736173Carcinoma, Non-Small-Cell Lung · United States, Hong Kong, Malaysia and more2CompletedArcus BiosciencesSep 17, 2026169
NCT04262856Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more2CompletedArcus BiosciencesJul 9, 2025151
NCT04087018Advanced Solid Tumors · United States1CompletedArcus BiosciencesJun 17, 202418
NCT03972722Uterine Cervical Neoplasms · China2UNKNOWNGuangzhou Gloria BiosciencesMay 15, 202289
NCT03846310Carcinoma, Non-Small-Cell Lung · United States, Korea, Republic of, Singapore and more1CompletedArcus BiosciencesNov 18, 202477
NCT03713905Advanced Solid Tumors · China1CompletedGuangzhou Gloria BiosciencesFeb 28, 2022293
NCT03655483Classical Hodgkin's Lymphoma · China2UNKNOWNGuangzhou Gloria BiosciencesApr 11, 202185
NCT03629756Carcinoma, Non-Small-Cell Lung · United States, Australia1CompletedArcus BiosciencesAug 18, 202148
NCT03547973Metastatic Urothelial Cancer · United States, France, Germany and more2Active, not recruitingGilead SciencesApr 2030502

How it is read

Names in the registry

  • “Zimberelimab”, 10 entries
  • “GLS-010”, 6 entries
  • “AB122”, 2 entries
  • “GLS-012+GLS-010”, 2 entries
  • “Zimberelimab (ZIM)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.